PriceTargets.com logo

Sabra Health Care REIT - SBRA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $19.33
  • Forecasted Upside: 12.73%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$17.15 As of 03/25/2025 05:00 PM ET
▼ -0.2 (-1.15%)

This chart shows the closing price for SBRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
JanFebMar$17.35Closing price on 03/24/25:
Get New Sabra Health Care REIT Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBRA

Analyst Price Target is $19.33
▲ +12.73% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Sabra Health Care REIT in the last 3 months. The average price target is $19.33, with a high forecast of $20.00 and a low forecast of $18.00. The average price target represents a 12.73% upside from the last price of $17.15.

This chart shows the closing price for SBRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/243/254/26$9.40$12$16$19$22Closing price on 03/24/25: $17.35High$20.00Average$19.33Low$18.00




Current Consensus is Moderate Buy

The current consensus among 7 contributing investment analysts is to moderate buy stock in Sabra Health Care REIT. This rating has held steady since November 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
10/2/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/23/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2025

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/18/2025Truist FinancialBoost TargetHold ➝ Hold$17.00 ➝ $18.00
1/17/2025Truist FinancialDowngradeBuy ➝ Hold$18.00 ➝ $17.00
1/7/2025Citizens JmpUpgradeHold ➝ Strong-Buy
1/7/2025JMP SecuritiesUpgradeMarket Perform ➝ Outperform$20.00
12/5/2024MizuhoReiterated RatingOutperform ➝ Neutral$20.00 ➝ $20.00
10/11/2024ScotiabankBoost TargetSector Perform ➝ Sector Perform$17.00 ➝ $18.00
10/1/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$16.00 ➝ $20.00
9/13/2024CitigroupUpgradeNeutral ➝ Buy$17.00 ➝ $20.00
9/4/2024Truist FinancialBoost TargetBuy ➝ Buy$16.00 ➝ $18.00
8/26/2024ScotiabankBoost TargetSector Perform ➝ Sector Perform$15.00 ➝ $17.00
6/27/2024Truist FinancialBoost TargetBuy ➝ Buy$15.00 ➝ $16.00
5/15/2024ScotiabankBoost TargetSector Perform ➝ Sector Perform$14.00 ➝ $15.00
2/29/2024WedbushReiterated RatingOutperform$17.00
1/30/2024Deutsche Bank AktiengesellschaftInitiated CoverageBuy$21.00
1/3/2024MizuhoBoost TargetBuy ➝ Buy$15.00 ➝ $17.00
11/7/2023Stifel NicolausBoost TargetBuy ➝ Buy$14.00 ➝ $16.00
10/17/2023BMO Capital MarketsReiterated RatingOutperform ➝ Market Perform$16.00
10/16/2023Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$13.00 ➝ $15.00
10/10/2023Bank of AmericaUpgradeNeutral ➝ Buy$14.00 ➝ $16.00
10/3/2023WedbushInitiated CoverageOutperform$16.00
9/29/2023Truist FinancialBoost Target$13.00 ➝ $15.00
9/20/2023Jefferies Financial GroupUpgradeHold ➝ Buy$11.00 ➝ $15.00
8/11/2023Bank of AmericaUpgradeUnderperform ➝ Neutral$11.00 ➝ $14.00
7/27/2023Berenberg BankInitiated CoverageHold$13.00
7/14/2023CitigroupBoost TargetNeutral$11.00 ➝ $12.50
5/4/2023Stifel NicolausLower Target$15.00 ➝ $14.00
4/25/2023BarclaysLower Target$15.00 ➝ $13.00
4/19/2023Wells Fargo & CompanyInitiated CoverageUnderweight$11.00
4/12/2023Credit Suisse GroupReiterated RatingNeutral$13.00
3/29/2023Truist FinancialLower TargetBuy$14.00 ➝ $13.00
3/28/2023CitigroupLower TargetNeutral$13.00 ➝ $10.50
12/13/2022JMP SecuritiesDowngradeOutperform ➝ Market Perform
11/14/2022Bank of AmericaDowngradeNeutral ➝ Underperform$15.00 ➝ $13.00
10/10/2022Robert W. BairdDowngradeOutperform ➝ Neutral$13.00
8/22/2022CitigroupBoost Target$15.50
8/9/2022BarclaysBoost Target$15.00
6/30/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$15.00 ➝ $14.00
6/3/2022Capital One FinancialInitiated CoverageEqual Weight ➝ Equal Weight$15.50
5/25/2022MizuhoUpgradeNeutral ➝ Buy$16.00 ➝ $15.00
4/18/2022BarclaysDowngradeOverweight ➝ Equal Weight$16.00 ➝ $14.00
4/4/2022Credit Suisse GroupBoost TargetNeutral$14.00 ➝ $15.00
3/11/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$15.00
2/23/2022Stifel NicolausLower TargetBuy$21.00 ➝ $18.00
2/22/2022BarclaysLower Target$19.00 ➝ $16.00
2/18/2022KeyCorpInitiated CoverageSector Weight ➝ Sector Weight
2/15/2022JMP SecuritiesLower TargetBuy$20.00 ➝ $16.00
2/1/2022Credit Suisse GroupInitiated CoverageNeutral$14.00
1/20/2022MizuhoLower Target$18.00 ➝ $16.00
10/7/2021Robert W. BairdInitiated CoverageOutperform$18.00
9/30/2021Truist FinancialUpgradeHold ➝ Buy$18.00
9/13/2021JMP SecuritiesLower TargetMarket Outperform$24.00 ➝ $20.00
5/21/2021BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$20.00 ➝ $21.00
5/9/2021Stifel NicolausUpgradeHold ➝ Buy$17.00 ➝ $21.00
1/13/2021MizuhoDowngradeBuy ➝ Neutral$18.00
1/13/2021Jefferies Financial GroupUpgradeHold ➝ Buy$17.00 ➝ $20.00
1/7/2021BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$19.00
12/15/2020Smith Barney CitigroupBoost Target$14.00 ➝ $17.00
12/3/2020JMP SecuritiesUpgradeMarket Perform ➝ Outperform$24.00
10/2/2020MizuhoBoost TargetBuy$14.00 ➝ $16.00
9/1/2020Stifel NicolausReiterated RatingHold$15.00
7/2/2020CitigroupBoost TargetNeutral$10.00 ➝ $14.00
6/23/2020ScotiabankUpgradeSector Underperform ➝ Sector Perform$12.00 ➝ $15.00
6/22/2020Wells Fargo & CompanyBoost TargetEqual Weight$13.00 ➝ $14.00
6/8/2020JMP SecuritiesInitiated CoverageMarket Perform
5/18/2020Berenberg BankUpgradeHold ➝ Buy$15.00
4/23/2020SunTrust BanksReiterated RatingHold$15.00
4/7/2020CitigroupLower TargetNeutral$20.00 ➝ $10.00
3/26/2020Wells Fargo & CompanyLower TargetEqual Weight$22.00 ➝ $10.50
(Data available from 3/25/2020 forward)

News Sentiment Rating

1.49 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/27/2024
  • 15 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2024
  • 18 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2024
  • 16 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2024
  • 23 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2024
  • 11 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2025
  • 18 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2025
  • 20 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2025

Current Sentiment

  • 20 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Sabra Health Care REIT logo
Sabra Health Care REIT, Inc. engages in the business of acquiring, financing, and owning real estate property. The company was founded on May 10, 2010 and is headquartered in Tustin, CA.
Read More

Today's Range

Now: $17.15
Low: $17.07
High: $17.41

50 Day Range

MA: $16.80
Low: $15.88
High: $17.78

52 Week Range

Now: $17.15
Low: $13.31
High: $20.03

Volume

2,061,955 shs

Average Volume

1,981,775 shs

Market Capitalization

$4.08 billion

P/E Ratio

32.36

Dividend Yield

6.92%

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Sabra Health Care REIT?

The following Wall Street research analysts have issued stock ratings on Sabra Health Care REIT in the last twelve months: Citigroup Inc., Citizens Jmp, JMP Securities, Mizuho, Scotiabank, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for SBRA.

What is the current price target for Sabra Health Care REIT?

0 Wall Street analysts have set twelve-month price targets for Sabra Health Care REIT in the last year. Their average twelve-month price target is $19.33, suggesting a possible upside of 12.6%. Wells Fargo & Company has the highest price target set, predicting SBRA will reach $20.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $18.00 for Sabra Health Care REIT in the next year.
View the latest price targets for SBRA.

What is the current consensus analyst rating for Sabra Health Care REIT?

Sabra Health Care REIT currently has 3 hold ratings, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SBRA.

What other companies compete with Sabra Health Care REIT?

Other companies that are similar to Sabra Health Care REIT include Omega Healthcare Investors, CubeSmart, Healthcare Realty Trust, Ryman Hospitality Properties and Rayonier. Learn More about companies similar to Sabra Health Care REIT.

How do I contact Sabra Health Care REIT's investor relations team?

Sabra Health Care REIT's physical mailing address is 18500 VON KARMAN AVENUE SUITE 550, IRVINE CA, 92612. The real estate investment trust's listed phone number is (888) 393-8248 and its investor relations email address is investorrelations@sabrahealth.com. The official website for Sabra Health Care REIT is www.sabrahealth.com. Learn More about contacing Sabra Health Care REIT investor relations.





Receive Sabra Health Care REIT News & Ratings Daily
Sign up to receive the latest news and ratings for Sabra Health Care REIT and its competitors with PriceTargets.com’s free daily newsletter.